Norfloxacin 400mg tablets
Requires a prescription from a doctor or prescriber
A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Norfloxacin
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Norfloxacin
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
9 branded products available
WHO defined daily dose (DDD)
800 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 30 studies.
Reviews & meta-analyses: 3 · Randomised trials: 1 · 2019–2026
Showing all 30 studies, sorted by most relevant.
J. Karp, W. Merz, C. Hendricksen, et al.
Annals of internal medicine, 2020
- Acute Disease
- Agranulocytosis
- Antineoplastic Agents
Yun Li, J. Bu, Yirui Sun, et al.
Separation and Purification Technology, 2024
Biming Liu, Wenbin Song, Haixia Wu, et al.
Chemical Engineering Journal, 2020
Mu Xi, Kangping Cui, Minshu Cui, et al.
Chemical Engineering Journal, 2021
Hai Chen, Jianlong Wang
Journal of hazardous materials, 2021
- Ozone
- Water Pollutants, Chemical
- Catalysis
Mrinmoy Barman, Syed Mahmood, R. Augustine, et al.
International journal of biological macromolecules, 2020
- Clay
- Anti-Bacterial Agents
- Delayed-Action Preparations
Zexi Zhou, Xiaohui Wen, Chaoting Shi, et al.
Food chemistry, 2023
- Metal-Organic Frameworks
- Lanthanoid Series Elements
- Cattle
Man Shuaishuai, Hebin Bao, Ke Xu, et al.
Chemical Engineering Journal, 2021
Shijie Li, Kexin Dong, M. Cai, et al.
eScience, 2023
Present photocatalysts for the synchronous cleanup of pharmaceuticals and heavy metals have several drawbacks, including inadequate reactive sites, inefficient electron–hole disassociation, and insufficient oxidation and reduction power. In this research, we sought to address these issues by using a facile solvothermal-photoreduction route to develop an innovative plasmonic S-scheme heterojunction, Au/MIL-101(Fe)/BiOBr. The screened-out Au/MIL-101(Fe)/BiOBr (AMB-2) works in a durable and high-performance manner for both Cr(VI) and norfloxacin (NOR) eradication under visible light, manifesting up to 53.3 and 2 times greater Cr(VI) and NOR abatement rates, respectively, than BiOBr. Remarkably, AMB-2’s ability to remove Cr(VI) in a Cr(VI)-NOR co-existence system is appreciably better than in a sole-Cr(VI) environment; the synergy among Cr(VI), NOR, and AMB-2 results in the better utilization of photo-induced carriers, yielding a desirable capacity for decontaminating Cr(VI) and NOR synchronously. The integration of MOF-based S-scheme heterojunctions and a plasmonic effect contributes to markedly reinforced photocatalytic ability by increasing the number of active sites, augmenting the visible-light absorbance, boosting the efficient disassociation and redistribution of powerful photo-carriers, and elevating the generation of reactive substances. We provide details of the photocatalytic mechanism, NOR decomposition process, and bio-toxicity of the intermediates. This synergistic strategy of modifying S-scheme heterojunctions with a noble metal opens new horizons for devising excellent MOF-based photosystems with a plasmonic effect for environment purification.
Abstract licence: CC BY
J. Georgin, D. Franco, Lucas Meili, et al.
Advances in colloid and interface science, 2024
- Water Pollutants, Chemical
- Environmental Restoration and Remediation
- Adsorption
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
85 found
Half-life
3-4 hours
Mechanism
The bactericidal action of Norfloxacin results from inhibition of the enzymes to…
Food interactions
3 warnings
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
3-4 hours
Protein binding
15%
Metabolism
Elimination
275 mL/min
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1071 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
PMID:17567603 PMID:18790802 PMID:22013166 PMID:22323612
May play a role in regulating the period length of BMAL1 transcriptional oscillation (By similarity)
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:10454528 PMID:10525100 PMID:10966938 PMID:17509700 PMID:20722056 PMID:33124720
Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium.
Relative uptake activity ratio of carnitine to TEA is 11.3 .
PMID:10454528 PMID:10525100 PMID:10966938
In intestinal epithelia, transports the quorum-sensing pentapeptide CSF (competence and sporulation factor) from B.subtilis which induces cytoprotective heat shock proteins contributing to intestinal homeostasis .
PMID:18005709
May also contribute to regulate the transport of organic compounds in testis across the blood-testis-barrier (Probable)
PMID:11669456 PMID:11907186 PMID:14675047 PMID:22108572 PMID:23832370 PMID:28534121 PMID:9950961
Mediates the uptake of OA across the basolateral side of proximal tubule epithelial cells, thereby contributing to the renal elimination of endogenous OA from the systemic circulation into the urine .
PMID:9887087
Functions as a biopterin transporters involved in the uptake and the secretion of coenzymes tetrahydrobiopterin (BH4), dihydrobiopterin (BH2) and sepiapterin to urine, thereby determining baseline levels of blood biopterins .
PMID:28534121
Transports prostaglandin E2 (PGE2) and prostaglandin F2-alpha (PGF2-alpha) and may contribute to their renal excretion .
PMID:11907186
Also mediates the uptake of cyclic nucleotides such as cAMP and cGMP .
PMID:26377792
Involved in the transport of neuroactive tryptophan metabolites kynurenate (KYNA) and xanthurenate (XA) and may contribute to their secretion from the brain .
PMID:22108572 PMID:23832370
May transport glutamate .
PMID:26377792
Also involved in the disposition of uremic toxins and potentially toxic xenobiotics by the renal organic anion secretory pathway, helping reduce their undesired toxicological effects on the body .
PMID:11669456 PMID:14675047
Uremic toxins include the indoxyl sulfate (IS), hippurate/N-benzoylglycine (HA), indole acetate (IA), 3-carboxy-4- methyl-5-propyl-2-furanpropionate (CMPF) and urate .
PMID:14675047 PMID:26377792
Xenobiotics include the mycotoxin ochratoxin (OTA) .
PMID:11669456
May also contribute to the transport of organic compounds in testes across the blood-testis-barrier PMID:35307651
ATC J01RA14
ATC J01RA13
ATC S01AE02
ATC J01MA06
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Norfloxacin
Additional database identifiers
Drugs Product Database (DPD)
1838
ChemSpider
4380
BindingDB
50045000
ZINC
ZINC000000003742
GenBank Gene Database
L42023
GenBank Protein Database
1574722
UniProt Accession
GYRA_HAEIN
GenBank Gene Database
L42023
GenBank Protein Database
1574370
UniProt Accession
PARC_HAEIN
GenBank Gene Database
X71437
UniProt Accession
GYRB_STAAU
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11989
GenAtlas
TOP2A
GeneCards
TOP2A
GenBank Gene Database
J04088
GenBank Protein Database
292830
Guide to Pharmacology
2637
UniProt Accession
TOP2A_HUMAN
UniProt Accession
GYRA_STAAU
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11989
GenAtlas
TOP2A
GeneCards
TOP2A
GenBank Gene Database
J04088
GenBank Protein Database
292830
Guide to Pharmacology
2637
UniProt Accession
TOP2A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11990
GenAtlas
TOP2B
GeneCards
TOP2B
GenBank Gene Database
X68060
UniProt Accession
TOP2B_HUMAN
UniProt Accession
PARC_STAAU
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2596
GenAtlas
CYP1A2
GeneCards
CYP1A2
GenBank Gene Database
Z00036
Guide to Pharmacology
1319
UniProt Accession
CP1A2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2595
GeneCards
CYP1A1
GenBank Gene Database
K03191
GenBank Protein Database
181276
Guide to Pharmacology
1318
UniProt Accession
CP1A1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2640
GeneCards
CYP3A7
GenBank Gene Database
D00408
GenBank Protein Database
220149
UniProt Accession
CP3A7_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10969
GenAtlas
SLC22A5
GeneCards
SLC22A5
GenBank Gene Database
AF057164
GenBank Protein Database
3273741
UniProt Accession
S22A5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10970
GenAtlas
hROAT1
GeneCards
SLC22A6
GenBank Gene Database
AF057039
GenBank Protein Database
3831566
Guide to Pharmacology
1025
UniProt Accession
S22A6_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Linked open data from Wikidata (Q417897), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.